BACKGROUND: Limited data are available on characteristics of viral encephalitis in patients after allogeneic stem cell transplantation. DESIGN AND METHODS: We analyzed 2,628 patients after allogeneic stem cell transplantation to identify risk factors and characteristics of viral encephalitis. RESULTS: Viral encephalitis occurred in 32 patients (1.2%, 95% confidence interval 0.8%-1.6%) and was associated with the use of OKT-3 or alemtuzumab for T-cell depletion (P < 0.001) and an increased mortality (P = 0.011) in comparison to patients without viral encephalitis. Detected viruses included human herpesvirus-6 (28%), Epstein-Barr virus (19%), herpes simplex virus (13%), JC virus (9%), varicella zoster virus (6%), cytomegalovirus (6%) and adenovirus (3%). More than one virus was identified in 16% of the patients. The median onset time was 106 days after allogeneic stem cell transplantation for the total group of 32 patients, but onset times were shortest in those with human herpesvirus-6 encephalitis and longest in those with JC virus-associated progressive multifocal leukoencephalopathy. The probability of a sustained response to treatment was 63% (95% confidence interval 44%-82%) with a median survival of 94 (95% confidence interval 36-152) days after onset, but significant variation was found when considering different causative viruses. Patients with herpes simplex virus encephalitis had the most favorable outcome with no encephalitis-related deaths. CONCLUSIONS: The use of OKT-3 or alemtuzumab for in vivo T-cell depletion is associated with an increased risk of viral encephalitis after allogeneic stem cell transplantation. Different viruses are frequently associated with distinct characteristics such as onset time, response to treatment and outcome.
BACKGROUND: Limited data are available on characteristics of viral encephalitis in patients after allogeneic stem cell transplantation. DESIGN AND METHODS: We analyzed 2,628 patients after allogeneic stem cell transplantation to identify risk factors and characteristics of viral encephalitis. RESULTS:Viral encephalitis occurred in 32 patients (1.2%, 95% confidence interval 0.8%-1.6%) and was associated with the use of OKT-3 or alemtuzumab for T-cell depletion (P < 0.001) and an increased mortality (P = 0.011) in comparison to patients without viral encephalitis. Detected viruses included human herpesvirus-6 (28%), Epstein-Barr virus (19%), herpes simplex virus (13%), JC virus (9%), varicella zoster virus (6%), cytomegalovirus (6%) and adenovirus (3%). More than one virus was identified in 16% of the patients. The median onset time was 106 days after allogeneic stem cell transplantation for the total group of 32 patients, but onset times were shortest in those with human herpesvirus-6 encephalitis and longest in those with JC virus-associated progressive multifocal leukoencephalopathy. The probability of a sustained response to treatment was 63% (95% confidence interval 44%-82%) with a median survival of 94 (95% confidence interval 36-152) days after onset, but significant variation was found when considering different causative viruses. Patients with herpes simplex virus encephalitis had the most favorable outcome with no encephalitis-related deaths. CONCLUSIONS: The use of OKT-3 or alemtuzumab for in vivo T-cell depletion is associated with an increased risk of viral encephalitis after allogeneic stem cell transplantation. Different viruses are frequently associated with distinct characteristics such as onset time, response to treatment and outcome.
Authors: F Broccolo; R Iuliano; A M Careddu; R Trovato; S Lico; P L Blanc; F Mazzotta; L Ceccherini-Nelli Journal: Acta Virol Date: 2000 Jun-Aug Impact factor: 1.162
Authors: Suparno Chakrabarti; Stephen Mackinnon; Raj Chopra; Panagiotis D Kottaridis; Karl Peggs; Peter O'Gorman; Ronjon Chakraverty; Timothy Marshall; Husam Osman; Premini Mahendra; Charles Craddock; Herman Waldmann; Geoff Hale; Christopher D Fegan; Kwee Yong; Anthony H Goldstone; David C Linch; Donald W Milligan Journal: Blood Date: 2002-06-15 Impact factor: 22.113
Authors: E Roemer; I W Blau; N Basara; M G Kiehl; M Bischoff; S Günzelmann; D Kirsten; H Sanchez; E L Wocker; A A Fauser Journal: Clin Infect Dis Date: 2000-12-11 Impact factor: 9.079
Authors: C Quereda; I Corral; F Laguna; M E Valencia; A Tenorio; J E Echeverria; E Navas; P Martín-Dávila; A Moreno; V Moreno; J M Gonzalez-Lahoz; J R Arribas; A Guerrero Journal: J Clin Microbiol Date: 2000-08 Impact factor: 5.948
Authors: Martin Schmidt-Hieber; S Schwarck; A Stroux; S Ganepola; P Reinke; E Thiel; L Uharek; I W Blau Journal: Int J Hematol Date: 2010-05-21 Impact factor: 2.490
Authors: Oluwole O Awosika; Jennifer L Lyons; Pedro Ciarlini; Richard E Phillips; Elizabeth D Alfson; Emily L Johnson; Sophia Koo; Francisco Marty; Clifton Drew; Sherif Zaki; Rebecca D Folkerth; Joshua P Klein Journal: Neurology Date: 2013-04-17 Impact factor: 9.910
Authors: M R Dowling; S Li; B R Dey; S L McAfee; H R Hock; T R Spitzer; Y-B Chen; K K Ballen Journal: Bone Marrow Transplant Date: 2017-11-13 Impact factor: 5.483